Compare Fubotv Inc (FUBO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Merck & Co., Inc. — how do they compare? Fubotv Inc trades at $10.45 (market cap $302.39M), while Merck & Co., Inc. trades at $127.92 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 1009.6× Fubotv Inc's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| FUBO | MRK | |
|---|---|---|
Market Cap | $302.39M | $305.29B |
Sector | Technology | Health |
52-Week High | $54.72 | $129.52 |
52-Week Low | $8.09 | $77.60 |
Enterprise Value | $472.81M | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO stock trades at $10.46, up 9.64% on the day, with a bullish technical signal and strong analyst support. The company shows improving fundamentals, with revenue reaching $1.62B in 2024 and a projected net profit of $123M in 2025. Recent CEO appointment of former Disney+ executive Alisa Bowen has driven positive sentiment, while valuation ratios like P/E of 2.67 and P/S of 0.21 appear attractive relative to historical norms.
The outlook for FUBO is cautiously optimistic, with upside to the $16.25 consensus price target, but risks include persistent cash flow challenges and intense streaming competition. Investors should weigh the potential for profitability growth against execution risks in a crowded market.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
